Literature DB >> 17716637

Overlapping paclitaxel-eluting stents: long-term effects in a porcine coronary artery model.

Gregory J Wilson1, Jason E Polovick, Barbara A Huibregtse, Bradley C Poff.   

Abstract

OBJECTIVE: At 4-year follow-up, paclitaxel-eluting stents (PES, TAXUS) have demonstrated clinical effectiveness in reducing restenosis without increasing death or myocardial infarction. Concerns remain with all drug-eluting stents, however, regarding potential interference with long-term healing, particularly in zones with adjacent stent overlap due to theoretical doubling in both drug release and tissue contact with coating polymer. Therefore, we evaluated long-term healing of overlapped TAXUS stents in an accepted animal model.
METHODS: Seventy-one non-injured swine underwent coronary artery placement of 138 overlapping stent-pairs (91 PES TAXUS Liberté 1 microg/mm(2) slow release formulation, 3.0 or 3.5 mm diameter pairs and 47 control bare metal Liberté pairs) deployed at a 1.1:1 to 1.2:1 target stent-to-artery diameter ratio. Pathological analysis was performed at 30 (9 bare, 10 paclitaxel), 90 (9 bare, 10 paclitaxel), 180 (10 bare, 16 paclitaxel), 360 (10 bare, 21 paclitaxel), and 580 (9 bare, 22 paclitaxel) days.
RESULTS: At all time intervals overlapped TAXUS stents were consistently endothelialized and free of luminal thrombus or vascular dilatation. Full healing, however, was delayed compared to control, with macrophage processed para-strut fibrin and cellular debris still present, but reduced and sequestered from blood flow by an endothelialized neointima at 360 and 580 days. While neointimal thickness in TAXUS overlap zones was significantly less than control at 30 days, greater neointima formation was observed with TAXUS at > or =90 days, but was stable and did not progress further from 90 to 580 days.
CONCLUSION: In this porcine model TAXUS stents demonstrated safety and acceptable healing with prolonged time to resolution of para-strut deposits, and did not produce the sustained neointimal suppression seen clinically.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716637     DOI: 10.1016/j.cardiores.2007.07.004

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  5 in total

1.  Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation.

Authors:  Robert S Schwartz; Elazer Edelman; Renu Virmani; Andrew Carter; Juan F Granada; Greg L Kaluza; Nicolas A F Chronos; Keith A Robinson; Ron Waksman; Judah Weinberger; Gregory J Wilson; Robert L Wilensky
Journal:  Circ Cardiovasc Interv       Date:  2008-10       Impact factor: 6.546

2.  Safety and efficacy of overlapping homogenous drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction Registry.

Authors:  Khurshid Ahmed; Myung Ho Jeong; Rabin Chakraborty; Young Joon Hong; Doo Sun Sim; Sumera Ahmed; Seung Hwan Hwang; Min Goo Lee; Keun Ho Park; Ju Han Kim; Youngkeun Ahn; Myeong Chan Cho; Chong Jin Kim; Young Jo Kim; Jong Chun Park; Jung Chaee Kang
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

3.  Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.

Authors:  Alexander Sheehy; Steven Hsu; Amelie Bouchard; Pablo Lema; Claudine Savard; Louis-Georges Guy; Julie Tai; Igor Polyakov
Journal:  Cardiovasc Diabetol       Date:  2012-06-21       Impact factor: 9.951

4.  Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions.

Authors:  S E Kassaian; M Salarifar; M Raissi Dehkordi; M Alidoosti; E Nematipour; H R Poorhosseini; A M Hajizeinali; D Kazemisaleh; A Sharafi; M Mahmoodian; N Paydari; A V Farahani
Journal:  Cardiovasc J Afr       Date:  2010 Nov-Dec       Impact factor: 1.167

5.  A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program.

Authors:  Dominic J Allocco; Louis A Cannon; Amy Britt; John E Heil; Andrey Nersesov; Scott Wehrenberg; Keith D Dawkins; Dean J Kereiakes
Journal:  Trials       Date:  2010-01-07       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.